Case Study: a leading diabetes drug company improves patient outcomes and cost insights with EXL's HEOR solution

Understanding the patient journey to ensure that a diabetes drug continues to lead the market

EXL worked with a leading diabetes drug company that needed a better understanding of the total cost of care and the full patient journey for its therapy compared with other diabetes drugs. In a crowded market with many treatment options, the company wanted to see how outcomes and costs changed over time so it could support value-based discussions with payers.

Using EXL’s Health Economics and Outcomes Research (HEOR) solution, the company analyzed claims data across major diabetes drug classes, tracked patients through four lines of therapy, and reviewed utilization, risk, and cost trends with interactive dashboards. EXL’s analysis showed that more than 50% of patients moved up to higher levels of treatment and that insulin patients had the highest total cost of care, helping the company refine market access messaging, identify new patient opportunities, and strengthen negotiations around value-based contracts.